PMID- 29212167
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 55
DP  - 2017 Nov 7
TI  - A nomogram to predict HER2 status in breast cancer patients with HER2-borderline 
      disease as determined via immunohistochemistry.
PG  - 93492-93501
LID - 10.18632/oncotarget.19313 [doi]
AB  - This study aimed to develop a nomogram to predict fluorescence in situ 
      hybridization (FISH) assay results for HER2-borderline breast cancer as 
      determined via immunohistochemistry (IHC) among patients in China. We reviewed a 
      database of breast cancer patients diagnosed between January 2007 and April 2013 
      at our institutions. We used logistic regression to develop a nomogram and we 
      used receiver operating characteristic curve analysis and calibration plots to 
      validate our nomogram. In total, 1138, 301 and 344 patients had IHC-determined 
      HER2-negative, HER2-borderline and HER2-positive disease, respectively. Within 
      the training cohort, univariate and multivariate analyses suggested that estrogen 
      receptor (ER) status, progesterone receptor (PR) status and tumor grade were 
      significantly associated with HER2 status (P<0.01). A nomogram was developed and 
      the AUCs for the training and validation cohorts were 0.795 and 0.749, 
      respectively. The calibration plots suggested that the model was well calibrated. 
      This new nomogram can be used to predict HER2 status in HER2-borderline breast 
      cancer patients and will be particularly helpful to resource-limited countries.
FAU - Guo, Qianqian
AU  - Guo Q
AD  - Department of Mammary Disease, Guangdong Provincial Hospital of Chinese Medicine, 
      Guangzhou, Guangdong, P.R. China.
FAU - Chen, Kai
AU  - Chen K
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 
      Guangdong, P.R. China.
AD  - Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 
      Guangzhou, Guangdong, P.R. China.
FAU - Lin, Xiaojie
AU  - Lin X
AD  - Department of Mammary Disease, Guangdong Provincial Hospital of Chinese Medicine, 
      Guangzhou, Guangdong, P.R. China.
FAU - Su, Yi
AU  - Su Y
AD  - Department of Intensive Care, Foshan Hospital of Traditional Chinese Medicine, 
      Guangzhou, Guangdong, P.R. China.
FAU - Xu, Rui
AU  - Xu R
AD  - Department of Mammary Disease, Guangdong Provincial Hospital of Chinese Medicine, 
      Guangzhou, Guangdong, P.R. China.
FAU - Dai, Yan
AU  - Dai Y
AD  - Department of Mammary Disease, Guangdong Provincial Hospital of Chinese Medicine, 
      Guangzhou, Guangdong, P.R. China.
FAU - Qiu, Chang
AU  - Qiu C
AD  - Department of Mammary Disease, Guangdong Provincial Hospital of Chinese Medicine, 
      Guangzhou, Guangdong, P.R. China.
FAU - Song, Xue
AU  - Song X
AD  - Department of Mammary Disease, Guangdong Provincial Hospital of Chinese Medicine, 
      Guangzhou, Guangdong, P.R. China.
FAU - Mao, Siying
AU  - Mao S
AD  - Department of Mammary Disease, Guangdong Provincial Hospital of Chinese Medicine, 
      Guangzhou, Guangdong, P.R. China.
FAU - Chen, Qianjun
AU  - Chen Q
AD  - Department of Mammary Disease, Guangdong Provincial Hospital of Chinese Medicine, 
      Guangzhou, Guangdong, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20170717
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5706813
OTO - NOTNLM
OT  - HER2 status
OT  - IHC
OT  - breast cancer
OT  - calibration
OT  - nomogram
COIS- CONFLICTS OF INTEREST The authors declare no conflicts of interest.
EDAT- 2017/12/08 06:00
MHDA- 2017/12/08 06:01
PMCR- 2017/11/07
CRDT- 2017/12/08 06:00
PHST- 2016/10/27 00:00 [received]
PHST- 2017/03/11 00:00 [accepted]
PHST- 2017/12/08 06:00 [entrez]
PHST- 2017/12/08 06:00 [pubmed]
PHST- 2017/12/08 06:01 [medline]
PHST- 2017/11/07 00:00 [pmc-release]
AID - 19313 [pii]
AID - 10.18632/oncotarget.19313 [doi]
PST - epublish
SO  - Oncotarget. 2017 Jul 17;8(55):93492-93501. doi: 10.18632/oncotarget.19313. 
      eCollection 2017 Nov 7.